Vancomycin monitoring in children using bayesian estimation

Therapeutic Drug Monitoring

Volumn 36, Issue 4, 2014, Pages 510-518

  Le, Jennifer ^a,b   Ngu, Becky ^b   Bradley, John S ^a,c   Murray, William ^c   Nguyen, Austin ^a   Nguyen, Lyn ^b   Romanowski, Gale L ^c   Vo, Tiana ^a   Capparelli, Edmund V ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b MILLER CHILDREN S HOSPITAL   (United States)

^c RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

Accuracy; Pediatrics; Pharmacokinetics; Therapeutic drug monitoring; Vancomycin

Indexed keywords

CREATININE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CHILD; CREATININE BLOOD LEVEL; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; ADOLESCENT; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; MULTICENTER STUDY; PRESCHOOL CHILD; RETROSPECTIVE STUDY;

ADOLESCENT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BAYES THEOREM; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; HUMANS; MALE; MODELS, BIOLOGICAL; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 84904577060     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000039     Document Type: Article

References (29)

1. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillinresistant staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285-292.
2. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Am J Health Syst Pharm. 2009;66:82-98.
3. Kullar R, Davis SL, Taylor TN, et al. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy. 2012;32:195-201.
4. Le J, Bradley JS, Murray W, et al. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013;32:e155-e163.
5. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American society of health-system pharmacists, the infectious diseases society of america, and the society of infectious diseases pharmacists. Pharmacotherapy. 2009;29:1275-1279.
6. Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant staphylococcal infections. Pediatr Infect Dis J. 2013;32:1077-1079.
7. Gordon CL, Thompson C, Carapetis JR, et al. Trough concentrations of vancomycin: adult therapeutic targets are not appropriate for children. Pediatr Infect Dis J. 2012;31:1269-1271.
8. Moffett BS, Edwards MS. Analysis of vancomycin therapeutic drug monitoring trends at pediatric hospitals. Pediatr Infect Dis J. 2013;32: 32-35.
9. Suryadevara M, Steidl KE, Probst LA, et al. Inappropriate vancomycin therapeutic drug monitoring in hospitalized pediatric patients increases pediatric trauma and hospital costs. J Pediatr Pharmacol Ther. 2012;17: 159-165.
10. McKamy S, Hernandez E, Jahng M, et al. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr. 2011;158:422-426.
11. Cies JJ, Shankar V. Nephrotoxicity in patients with vancomycin trough concentrations of 15-20 m/ml in a pediatric intensive care unit. Pharmacotherapy. 2013;33:392-400.
12. Totapally BR, Machado J, Lee H, et al. Acute kidney injury during vancomycin therapy in critically ill children. Pharmacotherapy. 2013; 33:598-602.
13. Neely MN, Youn G, Jones B, et al. Are vancomycin troughs adequate for optimal dosing? Antimicrob Agents Chemother. 2014;58:309-316.
14. Rybak MJ, Boike SC. Monitoring vancomycin therapy. Drug Intell Clin Pharm. 1986;20:757-761.
15. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166:2138-2144.
16. Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43: 925-942.
17. Suzuki Y, Kawasaki K, Sato Y, et al. Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokineticpharmacodynamic analysis in patients with methicillin-resistant staphylococcus aureus pneumonia. Chemotherapy. 2012;58:308-312.
18. Le J, Bradley JS, Murray W, et al. Vancomycin dosing in children by area-under-the curve (AUC). Paper presented at: 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2011; Chicago, IL.
19. Al-Khatib M, Shapiro RJ, Partovi N, et al. Limited sampling strategies for predicting area under the concentration-time curve of mycophenolic acid in islet transplant recipients. Ann Pharmacother. 2010;44:19-27.
20. Kim JS, Nafziger AN, Tsunoda SM, et al. Limited sampling strategy to predict AUC of the cyp3a phenotyping probe midazolam in adults: application to various assay techniques. J Clin Pharmacol. 2002;42:376-382.
21. Musuamba FT, Rousseau A, Bosmans JL, et al. Limited sampling models and bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. Clin Pharmacokinet. 2009;48:745-758.
22. Ting LS, Villeneuve E, Ensom MH. Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit. 2006;28:419-430.
23. Frymoyer A, Hersh AL, Benet LZ, et al. Current recommended dosing of vancomycin for children with invasive methicillin-resistant staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2009;28: 398-402.
24. Allegaert K, van den Anker JN. Creatinine-based vancomycin dosing regimens in neonates: there is more to consider than the variation in drug assay. Pharmacotherapy. 2012;32:e174; discussion e175.
25. Mehrotra N, Tang L, Phelps SJ, et al. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations. Pharmacotherapy. 2012;32:408-419.
26. Patel N, Pai MP, Rodvold KA, et al. Vancomycin: we can't get there from here. Clin Infect Dis. 2011;52:969-974.
27. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012; 54:755-771.
28. Saunders NJ. Why monitor peak vancomycin concentrations? Lancet. 1994;344:1748-1750.
29. Barclay ML, Duffull SB, Begg EJ, et al. Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve. Aust N Z J Med. 1995;25:230-235.